Brequinar - Clear Creek Bio
Alternative Names: Bipenquinate; Brequinar sodium; DUP 785; NSC 368390; NSC 369390Latest Information Update: 18 Aug 2022
At a glance
- Originator Bristol-Myers Squibb
- Developer Bristol-Myers Squibb; Clear Creek Bio
- Class Antineoplastics; Antivirals; Biphenyl compounds; Small molecules
- Mechanism of Action Dihydroorotate dehydrogenase inhibitors; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II COVID 2019 infections
- Phase I/II Acute myeloid leukaemia
- Discontinued Cancer; Cytomegalovirus infections; Transplant rejection
Most Recent Events
- 08 Aug 2022 Clear Creek Bio terminates a phase I/II trial in Acute myeloid leukemia in the US due to no efficacy observed (NCT03760666)
- 22 Jun 2022 Clear Creek Bio terminates the phase II CCBCRISIS04 trial for COVID-2019 infections (Combination therapy) in India (PO), due to low prevalence of COVID-19 in India led to lack of eligible subjects (NCT05166876)
- 22 Dec 2021 Clear Creek Bio plans a phase II trial CCBCRISIS04 for COVID- 2019 infections (Combination therapy) in India (PO) in December 2021 (NCT05166876)